natgillin/translations-raw huggingface dataset:
The main measure to indicate effectiveness of the medicine was the improvement in x-ray appearance of the wrists and knee joints of patients before and after treatment with Strensiq.
Glavno merilo učinkovitosti tega zdravila je bilo izboljšanje rentgenskega videza zapestnih in kolenskih sklepov bolnikov pred zdravljenjem z zdravilom Strensiq in po njem.
The main measures of effectiveness for the two studies were the change in pain intensity as measured on a pain scale and the number of patients who responded to treatment after ten minutes.
Glavni merili učinkovitosti v obeh študijah sta bili sprememba intenzivnosti bolečine, ocenjena na podlage bolečinske lestvice, in število bolnikov, ki so se po desetih minutah odzvali na zdravljenje.
The main measures of effectiveness were average daily weight gain during the finishing period, the level of PCV2 in the blood and a score for the severity of damage (lesions) to the lung.
Glavna merila učinkovitosti so bila povprečno dnevno pridobivanje telesne mase med zaključnim obdobjem, raven virusa PCV2 v krvi in ocena resnosti poškodbe pljuč oz. lezij v pljučih.
The main measures of effectiveness were based on how well the medicines maintained the required sedation level and the time patients needed to spend on a mechanical ventilator.
Glavno merilo učinkovitosti je bilo, kako dobro je zdravilo vzdrževalo želeno stopnjo sedacije, in čas, ki ga je bolnik moral preživeti na respiratorju.
The main measures of effectiveness were based on muscle strength and the reduction in patients’ disability.
Glavni merili učinkovitosti sta bili mišična moč in zmanjšanje bolnikove prizadetosti.
The main measures of effectiveness were based on the number of patients who had 20 or 50% reductions in the number and severity of symptoms after 14 or 24 weeks.
Glavno merilo učinkovitosti je temeljilo na številu bolnikov, pri katerih sta se po 14 ali 24 tednih za 20 ali 50 % zmanjšala število in resnost simptomov.
The main measures of effectiveness were based on the number of strokes or clotting events that occurred during treatment.
Glavno merilo učinkovitosti je bilo število kapi ali krvnih strdkov, ki so se pojavili med zdravljenjem.
The main measures of effectiveness were how long the patients lived (overall survival) and how long they lived without their disease getting worse (progression free survival).
Glavni merili učinkovitosti sta bili čas preživetja (celokupno preživetje) in čas preživetja brez poslabšanja bolezni (preživetje brez napredovanja bolezni).
The main measures of effectiveness were how long the patients survived or the length of time before the patient’s cancer started to get worse.
Glavno merilo učinkovitosti sta bila čas preživetja ali čas do poslabšanja rakavega obolenja.
The main measures of effectiveness were how well the defects had healed after one year and the change in the patients’ Knee Injury and Osteoarthritis Outcome Score (KOOS) after one and three years of treatment.
Glavni merili učinkovitosti sta bili dejstvo, kako dobro so se okvare popravile po enem letu, in sprememba v bolnikovem KOOS (Knee Injury and Osteoarthritis Outcome Score – merjenje izida ob poškodbi kolena in osteoartritisu) po enem in po treh letih od zdravljenja.
The main measures of effectiveness were improvement in symptom scores and in the level of amyloid A in the blood (another marker of inflammation).
Glavno merilo učinkovitosti sta bila izboljšanje ocene simptomov in raven amiloida A v krvi (drugega označevalca vnetja).
The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients’ scores on an incontinence-specific quality-of-life (I-QOL) questionnaire.
Glavni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (IEF), tj. število inkontinenčnih epizod na teden, razvidno iz dnevnikov zdravljenja, ter število točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I–QOL).
The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients’ scores on an incontinence-specific quality-of-life questionnaire (I-QOL).
Glavni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (IEF, tj. število inkontinenčnih epizod na teden), razvidno iz dnevnikov zdravljenja ter bolnikovega števila točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I-QOL).
The main measures of effectiveness were lung function (‘forced vital capacity’, the maximum amount of air the patient could breathe out), and the distance the patients could walk in six minutes, which measures the combined effects of the illness on the heart, lungs, joints and other organs.
Glavno merilo učinkovitosti je bilo delovanje pljuč (forsirana vitalna kapaciteta, tj. največja količina zraka, ki jo bolnik lahko naenkrat izdihne) in razdalja, ki jo bolnik lahko prehodi v šestih minutah, s čimer se merijo skupni učinki bolezni na srce, pljuča, sklepe in druge organe.
The main measures of effectiveness were pain intensity (measured on a scale from 0 to 100) 3 days after taking the medicine, as well as the time to a first new attack of gouty arthritis.
Glavni merili učinkovitosti sta bila intenzivnost bolečine (na lestvici od 0 do 100) tri dni po prejemu zdravila in čas do prvega ponovnega napada protinskega artritisa.
The main measures of effectiveness were progression-free survival and overall survival (the length of time the patients lived).
Glavni merili učinkovitosti sta bili čas preživetja bolnikov, med katerim bolezen ni napredovala, in celokupni čas preživetja.
The main measures of effectiveness were reductions in heavy bleeding and associated anaemia, as well as the size of the fibroids.
Glavno merilo učinkovitosti je bilo zmanjšanje močnih krvavitev in z njimi povezane anemije ter velikosti leiomiomov.
The main measures of effectiveness were respiratory and depression scores as well as body temperature.
Glavno merilo učinkovitosti sta bila rezultata dihanja in depresije ter telesna temperatura.
The main measures of effectiveness were the change in platelet count and the number of patients who achieved ‘platelet count normalisation’ and ‘haematological normalisation’ (their levels of platelets and lactate dehydrogenase, an enzyme normally found in red blood cells, were within normal levels).
Glavni merili učinkovitosti sta bili sprememba v številu trombocitov in število bolnikov, pri katerih je prišlo do normalizacije števila trombocitov in hematološke normalizacije (ravni trombocitov in laktat-hidrogenaze, tj. encima, ki je običajno v rdečih krvnih celicah, so bile normalne).
The main measures of effectiveness were the change in the level of HIV in the blood (viral load) and the change in the number of CD4 T-cells in the blood (CD4 cell count) after 12 weeks of treatment.
Glavni merili učinkovitosti sta bili sprememba ravni virusa HIV (virusne obremenitve) v krvi in sprememba števila T-celic CD4 v krvi po 12 tednih zdravljenja.
The main measures of effectiveness were the improvement in the distance the patients could walk in six minutes and in their ‘forced vital capacity’ (a measure of how well their lungs were working).
Glavni merili učinkovitosti sta bili povečanje razdalje, ki jo je bolnik lahko prehodil v šestih minutah, in njihova „forsirana vitalna kapaciteta“ (kako dobro delujejo pljuča).
The main measures of effectiveness were the improvement in the severity of symptoms or the healing of fistulae.
Glavno merilo učinkovitosti je bilo izboljšanje v zvezi z izraženostjo simptomov ali pa ozdravitev fistul.
The main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times: before vaccination, on the day of the second injection (day 21) and 21 days later (day 42).
Glavno merilo učinkovitosti je bila koncentracija protiteles proti virusu gripe v krvi v treh različnih obdobjih: pred cepljenjem, na dan prejema druge injekcije (21. dan) ter 21 dni kasneje (42. dan).
The main measures of effectiveness were the levels of antibodies against the flu virus in the patients’ blood before vaccination, on the day of the second injection (day 21), and 21 days later (day 42).
Glavna merila učinkovitosti so bile koncentracije protiteles proti virusu gripe v krvi bolnika pred cepljenjem, na dan drugega cepljenja (21. dan) in 21 dni kasneje (na 42. dan).
The main measures of effectiveness were the levels of antibodies against the flu virus in the patients’ blood before vaccination, on the day of the second injection (day 22), and 21 days later (day 43).
Glavna merila učinkovitosti so bile koncentracije protiteles proti virusu gripe v krvi bolnikov pred cepljenjem, na dan drugega cepljenja (22. dan) in 21 dni kasneje (43. dan).
The main measures of effectiveness were the number of patients whose bowels opened within four hours of the first dose, and the percentage of injections that were successful in producing a bowel movement.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so blato odvedli v štirih urah po prvem odmerku, in delež injekcij, ki so uspešno pospešile delovanje črevesja.
The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long it took for the disease to progress, how long the patients remained disease-free or how long they survived.
Glavna merila učinkovitosti so bila število bolnikov, pri katerih se je rak odzval na zdravljenje, čas do napredovanja bolezni, čas brez bolezni ali čas preživetja.
The main measures of effectiveness were the number of patients whose level of haemoglobin (a protein found in red blood cells) remained above their individual target level, and the number of red blood cell transfusions that the patients needed during the first 26 weeks of treatment.
Glavni merili učinkovitosti sta bili delež bolnikov, pri katerih je raven hemoglobina (beljakovine v rdečih krvničkah) ostala nad njihovo posamezno ciljno ravnjo, in število transfuzij rdečih krvnih celic, ki so jih bolniki potrebovali v prvih 26 tednih zdravljenja.
The main measures of effectiveness were the number of patients with myeloablation and ‘engraftment’ (the time for the transplanted stem cells to begin growing and for white blood cells to return to higher levels).
Glavni merili učinkovitosti sta bili število bolnikov z mieloablacijo in „prijetje presadka“ (čas, potreben za začetek rasti presajenih matičnih celic in povečanje števila belih krvnih telesc v obtoku).
The main measures of effectiveness were the numbers of patients who achieved ‘thrombotic microangiopathy event-free’ status (they did not have a decrease of over 25% in platelet count after starting Soliris and did not require plasma exchange or infusion, or dialysis) and the number of patients who achieved haematological normalisation while receiving Soliris.
Glavni merili učinkovitosti sta bili število bolnikov, pri katerih je bila trombotična mikroangiopatija brez neželenih dogodkov (po začetku jemanja zdravila Soliris se jim število trombocitov ni zmanjšalo za več kot 25 % in niso potrebovali izmenjave plazme, infuzije ali dialize), in število bolnikov, pri katerih je med jemanjem zdravila Soliris prišlo do hematološke normalizacije.
The main measures of effectiveness were the proportion of patients who had no visible tumour on a brain scan taken 72 hours after the operation, and the proportion who survived six months without the brain tumour coming back or getting bigger (‘progressing’).
Glavno merilo učinkovitosti sta bila delež bolnikov, ki na sliki možganov, posneti 72 ur po operaciji, ni imel vidnega tumorja, ter delež bolnikov, ki je 6 mesecev preživel brez ponovnega pojava tumorja ali njegove rasti (napredovanja).
The main measures of effectiveness were the reduction in symptoms of arthritis after treatment, as well as physical function (the ability to carry out everyday tasks) and the amount of damage to the joints (assessed using X-rays).
Glavna merila učinkovitosti so bila zmanjšanje simptomov artritisa po zdravljenju in fizična funkcija (sposobnost izvajanja vsakodnevnih nalog) ter obseg poškodb sklepov (ocenjen z rentgenskim pregledom).
The main measures of the efficacy of the vaccine were viraemia and clinical signs in animals that took part in the studies.
Glavni merili učinkovitosti cepiva so bili viremija in klinični znaki pri živalih, ki sodelovale v študijah.
The main measures were the overall rate of thrombotic events (blood clots causing
Glavno merilo je bilo skupno število
The main metabolic pathway for tegafur is through conversion to 5-FU via CYP2A6 in the liver, whereas gimeracil was stable in human liver homogenate (S9 fraction) with adenosine 3’-phosphate 5'-phosphosulfphate lithium salt (PAPS; a co-factor for sulfotransferase) or nicotinamide adenine dinucleotide phosphate (NADPH).
Glavna presnovna pot za tegafur poteka prek pretvorbe v 5-FU z encimom CYP2A6 v jetrih, medtem ko je gimeracil stabilen v homogenatu človeških jeter (frakcija S9) z adenozin 3’-fosfat 5'-fosfosulfat litijevo soljo (PAPS; kofaktor za sulfotransferazo) ali nikotinamid adenin dinukleotid fosfatom (NADPH).
The main metabolic pathway is glucuronidation of entacapone and its active metabolite, the cis-isomer, which accounts for about 5% of plasma total amount.
Glavna presnovna pot je glukuronizacija entakapona in njegovega aktivnega presnovka cis- izomera, ki predstavlja približno 5 % celotne količine v plazmi.
The main metabolic pathways in humans were identified as oxidation by aldehyde oxidase, demethylation via CYP3A4, glutathione conjugation with elimination of the O-aryl group (chlorbenzyl moiety), and combinations of these pathways followed by further biotransformations (e.g., glucuronidation, hydrolysis of the glutathione moiety, degradation of the cysteine moiety, and intramolecular rearrangement of the cysteinylglycine and cysteine conjugates with subsequent dimerisation).
Ugotovili so, da so poglavitne presnovne poti pri ljudeh oksidacija z aldehidno oksidazo, demetilacija s CYP3A4, konjugacija z glutationom z odstranitvijo O-arilne skupine (klorbenzilni del molekule) in kombinacije teh presnovnih poti, ki jim sledijo nadaljnje biotransformacije (npr. glukuronidacija, hidroliza glutationskega dela molekule, razgradnja cisteinskega dela molekule in intramolekulska prerazporeditev cisteinilglicinskih in cisteinskih konjugatov s poznejšo dimerizacijo).
The main metabolite is characterised as toltrazuril sulfone.
Glavni metabolit je označen kot toltrazuril sulfon.
The main metabolite M1 is approximately 10 times less potent than atosiban in inhibiting oxytocin- induced uterine contractions in vitro.
Glavni presnovek M1 je pri in vitro zaviranju z oksitocinom povzročene kontrakcije maternice približno 10-krat manj učinkovit od atosibana.
The main metabolite M1 is approximately 10 times less potent than atosiban in inhibiting oxytocin-induced uterine contractions in vitro.
Glavni presnovek M1 je pri in vitro zaviranju z oksitocinom povzročene kontrakcije maternice približno 10-krat manj učinkovit od atosibana.
The main metabolites are monohydroxycyclohexyl derivatives of praziquantel.
Glavni metaboliti so monohidroksi- cikloheksilni derivati prazikvantela.
The main metabolites are monohydroxycyclohexyl derivatives of praziquantel.
Glavni presnovki so monohidroksi-cikloheksilni derivati prazikvantela.
The main part of the study lasted for a year, but 13 patients carried on receiving the medicine for a further two years.
Glavni del študije je trajal eno leto, 13 bolnikov pa je zdravilo jemalo še nadaljnji dve leti.
The main primary endpoints of this study were the incidence and severity of adverse events associated with long-term exposure to ambrisentan, including serum LFTs.
Glavna primarna opazovana dogodka te študije sta bila incidenca in izrazitost , neželenih učinkov, povezanih z dolgotrajno izpostavljenostjo ambrisentanu, vključno s serumskimi LFT.
The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).
Glavni razlog za ukinitev zdravljenja bolnikom z velikim tumorskim bremenom v 1. ciklu zdravljenja v skupini z lenalidomidom so bili neželeni dogodki, 7/11 (64 %).
The main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).
Glavni razlog za ukinitev zdravljenja bolnikov z velikim tumorskim bremenom v 1. ciklu zdravljenja v skupini z lenalidomidom so bili neželeni dogodki, 7/11 (64 %).
The main risk factors for hyperkalaemia to be considered are:
Glavni dejavniki tveganja za hiperkaliemijo, ki jih je treba upoštevati, so:
The main risk factors for hyperkalaemia to be considered are:
Glavni dejavniki tveganja za pojav hiperkaliemije, ki jih je treba upoštevati, so:
The main route of elimination for 6–mercaptopurine is by metabolism.
Glavna pot eliminacije 6-merkaptopurina je s presnavljanjem.
The main routes of metabolism of ambrisentan are glucuronidation and oxidation with subsequent elimination in the bile and therefore hepatic impairment might be expected to increase exposure (Cmax and AUC) of ambrisentan.
Ker glavna presnovna pot ambrisentana poteka preko glukuronidacije in oksidacije ter kasnejšega izločanja z žolčem, lahko pričakujemo, da bi okvara jeter morda lahko povečala izpostavljenost (Cmax in AUC) ambrisentanu.
The main routes of metabolism of ambrisentan are glucuronidation and oxidation with subsequent elimination in the bile and therefore hepatic impairment might be expected to increase exposure (Cmax and AUC) of ambrisentan.
Ker glavna presnovna pot ambrisentana poteka preko glukuronidacije in oksidacije ter kasnejšega izločanja z žolčem, lahko pričakujemo, da se bi pri okvari jeter morda lahko povečala izpostavljenost (Cmax in AUC) ambrisentanu.
The main secondary endpoint “change in best VA” was measured as the difference between best VA in either the left or right eye at 24 weeks compared to baseline (Table 1).
Glavni sekundarni opazovani dogodek »sprememba najboljše VA« so merili kot razliko med najboljšo VA v levem ali desnem očesu po 24 tednih v primerjavi z izhodiščem.
The main side effects of Erbitux are infusion-related side effects and side effects concerning the skin:
Glavni neželeni učinki zdravila Erbitux so neželeni učinki, povezani z infundiranjem, in neželeni učinki, povezani s kožnimi reakcijami:
The main side effects seen with Activyl Tick Plus are transitory scratching, erythema (reddening of the skin) and hair loss at the application site.
Glavni neželeni učinki, ki so jih opazili pri uporabi zdravila Activyl Tick Plus, so prehodno praskanje, eritem (pordelost kože) ali izpadanje dlake na mestu nanosa.
The main signs of the illness include mild signs of flu such as headache or fever, feeling very tired, dark urine, pale stools (faeces), yellow skin or eyes (jaundice).
Med glavnimi znaki bolezni so blagi znaki gripe, npr. glavobol ali zvišana telesna temperatura, občutek hude utrujenosti, temen urin, bledo blato in porumenelost kože ali oči (zlatenica).
The main studies compared insulin glargine 100 units/ml given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
V glavnih študijah so prejemanje insulina glargina 100 enot/ml enkrat dnevno pred spanjem primerjali s prejemanjem človeškega insulina NPH (srednjedolgo delujočega insulina) enkrat ali dvakrat dnevno.
The main study in adults involved 277 patients with PAH, most of whom had class II or class III disease.
V glavno študijo pri odraslih je bilo vključenih 277 bolnikov s pljučno arterijsko hipertenzijo, večina katerih je imela bolezen razreda II ali III.
The main study of Atripla included 300 patients whose HIV infection was already being successfully treated with various combinations of antiviral medicines.
Glavna študija zdravila Atripla je vključevala 300 bolnikov, pri katerih je bila okužba z virusom HIV uspešno zdravljena z različnimi kombinacijami protivirusnih zdravil.
The main study of Inovelon involved 139 patients aged between four and 30 years, of whom three quarters were below 17 years old.
Glavna študija z zdravilom Inovelon je vključevala 139 bolnikov starih od štiri do 30 let, od katerih jih je bilo tri četrtine mlajših od 17 let.
The main study of Prepandrix included 675 healthy adults and compared the ability of Prepandrix, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity’).
V glavno študijo cepiva Prepandrix je bilo vključenih 675 zdravih odraslih oseb, primerjali pa so njegovo učinkovitost, z adjuvansom ali brez njega, pri sprožanju tvorbe protiteles („imunogenost“).
The main study of the vaccine included 400 healthy adults aged between 18 and 60 years and compared the ability of different doses of the vaccine, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity’).
V glavno študijo cepiva je bilo vključenih 400 zdravih odraslih oseb, starih od 18 do 60 let, v njej pa so primerjali učinkovitost različnih odmerkov virusa, z adjuvansom ali brez njega, pri sprožanju nastajanja protiteles („imunogenosti“).
The main study of the vaccine included 400 healthy adults aged between 18 and 60 years and compared the ability of different doses of the vaccine, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity’).
V glavno študijo cepiva je bilo vključenih 400 zdravih odraslih, starih od 18 do 60 let, v njej pa so primerjali učinkovitost različnih odmerkov virusa, z adjuvansom ali brez njega, pri sprožanju tvorbe protiteles („imunogenost“).
The main study showed that adding Empliciti to lenalidomide and dexamethasone can delay the worsening of multiple myeloma and improve response rates in patients whose disease had come back or did not respond to previous treatment.
Glavna študija je pokazala, da dodajanje zdravila Empliciti k lenalidomidu in deksametazonu lahko odloži poslabšanje multiplega mieloma in izboljša odziv pri bolnikih, ki se jim je bolezen ponovila oziroma so bili neodzivni na predhodno zdravljenje.
The main study showed that patients taking Zelboraf lived on average for 13.2 months compared with 9.9 months for patients on dacarbazine, and it took on average 5.3 months for the disease to worsen in the Zelboraf group compared with 1.6 months in the dacarbazine group.
Glavna študija je pokazala, da so bolniki, ki so jemali zdravilo Zelboraf v povprečju živeli 13,2 meseca, medtem ko so bolniki, ki so jemali dakarbazin, živeli 9,6 meseca.
The main symptoms of IBS with constipation include:
Glavni simptomi razdražljivega črevesja z zaprtjem vključujejo:
The main symptoms of IBS-D include:
Glavni simptomi IBS-D vključujejo:
The main target organs of toxicity in dogs are the gastrointestinal tract, the haematopoetic system, the kidney and the liver.
Glavni organi, pri katerih pride do zastrupitve pri psih, so prebavni trakt, hematopoetski sistem, ledvice in jetra.
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Glavni test za ugotavljanje HER2- pozitivnosti v tej odločilni študiji je bila imunohistokemija (IHK).
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Glavni test za ugotavljanje HER2-pozitivnosti v tej ključni študiji je bila imunohistokemija (IHK).
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Glavni test za ugotavljanje HER2-pozitivnosti v tej odločilni študiji je bila imunohistokemija (IHK).
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Glavni test za ugotavljanje HER2-pozitivnosti v tem ključnem preskušanju je bila imunohistokemija (IHK).
The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Glavni test za ugotavljanje HER2-pozitivnosti v tem odločilnem preskušanju je bila imunohistokemija (IHK).